CJC-1295: A Long-Acting GHRH Analog, Read Skeptically

The short version

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), the signal that tells the pituitary gland to release growth hormone (GH). Four amino-acid substitutions make it resistant to enzymatic breakdown, and in the 'DAC' (Drug Affinity Complex) form, a chemical linker binds it to albumin, a blood protein, stretching its activity from minutes to days. A short-acting version without that linker, sometimes called Modified GRF (1-29) or no-DAC, is often confused with the DAC form even though the two behave very differently.

CJC-1295 has never been approved for human use anywhere. The published human evidence is limited to a handful of small, early-phase pharmacology studies from the mid-2000s — real data, but not a case for safety or effectiveness at scale. A single-dose study found GH rose two- to ten-fold for six days or more, and IGF-1 rose one-and-a-half- to three-fold for over a week ^[4]. That is a genuine, measured effect — and also close to the extent of what is directly known.

What it is

CJC-1295 is a synthetic peptide built on the first 29 amino acids of human growth-hormone-releasing hormone, hGRF(1-29), carrying four substitutions — D-alanine at position 2, glutamine at 8, alanine at 15, and leucine at 27 — that stabilize its structure and block the enzymes that would otherwise break it down quickly. In the 'DAC' (Drug Affinity Complex) variant, a maleimidopropionyl linker on a C-terminal lysine forms a covalent bond with a free thiol on circulating serum albumin ^[8], anchoring the peptide to a long-lived blood protein and stretching its activity from minutes toward the multi-day lifespan of albumin itself. The version without that linker — Modified GRF (1-29), or 'no-DAC' — keeps the same four substitutions but lacks the albumin anchor, and is short-acting by comparison. The two forms are routinely conflated in marketing and forum discussion despite behaving very differently.

How it works

CJC-1295 binds the GHRH receptor on somatotrophs, the growth-hormone-producing cells of the anterior pituitary, activating a Gs-protein/cAMP signaling cascade that stimulates both the synthesis and the pulsatile release of GH. Because the DAC form stays bound to albumin for days, a single dose keeps GHRH-receptor signaling elevated well past the timescale of natural GHRH pulses — yet a dedicated human study found that GH continued to be released in its normal pulsatile pattern rather than as a flat, continuous elevation, suggesting the underlying pituitary release machinery is not overridden even under sustained stimulation ^[5]. The downstream consequence, mediated by the liver, is a rise in circulating IGF-1 that outlasts the GH elevation itself by several additional days ^[4].

What the research shows

Five published human studies make up the entire direct evidence base for CJC-1295, and none of them tests a therapeutic outcome — all measure pharmacodynamics or biomarkers in small groups of adults.

A 2025 review in a major endocrinology journal synthesizes GHRH-analog pharmacology broadly, including the receptor biology and design rationale behind long-acting analogs like CJC-1295, sermorelin, and tesamorelin ^[1] — useful framing, but a review rather than new primary data. A 2010 analytical-chemistry paper used high-resolution mass spectrometry to positively identify CJC-1295 as the active ingredient in an unlabeled 'GHRH' preparation seized in an anti-doping context ^[2] — a definitive identification, but not a safety or efficacy finding. In 11 healthy young men, CJC-1295 shifted several serum proteins (lower apolipoprotein A1, a changed transthyretin isoform, higher levels of an albumin fragment and an immunoglobulin-related species), and the albumin-fragment/immunoglobulin signal tracked linearly with IGF-1 — a candidate biomarker pattern from a study of eleven people ^[3]. The central pharmacodynamic study, in adults aged 21 to 61, found single 30- or 60-microgram-per-kilogram doses produced dose-dependent two- to ten-fold increases in mean GH for six days or more, and one-and-a-half- to three-fold increases in IGF-1 for nine to eleven days; after repeated dosing, IGF-1 remained elevated for up to 28 days, with an estimated CJC-1295 half-life of 5.8 to 8.1 days ^[4]. A companion study in men aged 20 to 40 found a single 60- or 90-microgram-per-kilogram dose raised basal (trough) GH roughly 7.5-fold and mean GH and IGF-1 by about 46% and 45% respectively a week later, while confirming that pulsatile GH secretion continued unaltered ^[5].

Taken together, these five sources establish that CJC-1295 measurably and durably raises GH and IGF-1 in small groups of healthy adults. They do not establish anything about a therapeutic use, a safe long-term dosing regimen, or an effect in any population outside those specific study cohorts.

Reported effects, cautions & safety

What follows on user-reported effects is anecdotal, not clinical evidence — patterns compiled from peptide-user forums, clinic blog summaries of client reports, and consumer peptide guides, not from any controlled trial of CJC-1295.

Reported benefits: The single most commonly reported effect is deeper, more restful sleep — often the first change people notice, consistent with GH's known release during deep sleep. Frequently reported next are faster recovery from training and reduced soreness, and gradual fat loss (especially around the midsection) that users describe emerging over three to six weeks alongside diet and exercise, alongside a leaner look and better muscle retention while dieting. Reported less consistently: more daytime energy, sharper focus, and firmer-feeling skin or connective tissue — effects users themselves often describe as secondary to better sleep.

Reported adverse effects: Water retention, bloating, and facial or hand puffiness is the most commonly reported downside, and users widely note it is more pronounced with the long-acting DAC form than the short-acting no-DAC version. Tingling or numbness in the hands, resembling mild carpal tunnel, and injection-site redness or swelling are frequently reported. Reported occasionally: a warm flush or brief head rush after injecting (more with no-DAC), fatigue or drowsiness (mixed with reports of the opposite), headache, increased appetite (mainly when paired with ipamorelin), and — in at least one widely discussed self-experiment — higher blood sugar or reduced insulin sensitivity from sustained GH elevation.

Cited cautions:

• Thin human evidence base. CJC-1295 is not approved for human use anywhere, and the published human pharmacology data are limited to a small number of early-phase studies in healthy volunteers ^[4][5] — not a safety or efficacy case for any specific use.
• Sustained IGF-1 elevation and a theoretical cancer link. Population-level studies have associated higher circulating IGF-1 with a modestly increased risk of certain cancers; because the DAC form keeps IGF-1 elevated for days at a stretch, this is a mechanism-based concern rather than a demonstrated one, and it applies most to people with a personal or family cancer history.
• Fluid retention and nerve-compression effects. GH causes the kidneys to retain sodium and water, the likely mechanism behind the water retention and hand tingling reported above; this is treated as a real physiological effect, not simply cosmetic bloating.
• Blood sugar and insulin sensitivity. GH is glucose-sparing, so sustained axis stimulation can reduce insulin sensitivity — a concern flagged most for people with diabetes, prediabetes, or existing insulin resistance.
• Regulatory unease over immunogenicity. A 2024 FDA compounding-committee review cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295 as part of its case against adding the compound to an approved compounding list — a current pharmacology review of the class ^[1] echoes similar considerations for long-acting, albumin-binding designs.
• A halted development program. The original long-acting DAC program ran a Phase 2 trial that was discontinued, and a patient death from that era is frequently cited alongside it; the public record does not establish that CJC-1295 caused that death, so this is unresolved history, not proof of harm.
• DAC and no-DAC are not the same compound, pharmacologically. The DAC linker chemistry that gives CJC-1295 its multi-day albumin-bound activity ^[8] is absent from the no-DAC (Modified GRF 1-29) form, which lasts minutes to hours — a distinction marketing and forum discussion routinely blur, with real consequences for interpreting any reported effect.
• Banned in sport. CJC-1295 is prohibited at all times under WADA Section S2, with established detection methods; this is a regulatory and eligibility risk distinct from any health effect.

Where it fits in the GH axis

CJC-1295 is the single-mechanism case on this desk: one receptor (GHRH-R), one signaling pathway (Gs/cAMP), and — because of the DAC albumin linker — one dose lasting days rather than minutes. The CJC-1295/ipamorelin combination keeps this same GHRH-receptor arm and adds a second, independent receptor pathway on top of it; MOTS-c abandons pituitary receptor signaling altogether and works through a mitochondrial-to-nucleus pathway instead. Reading the three together clarifies how much of 'GH axis research' is actually about the pituitary receptor versus the metabolic consequences downstream of it. See the comparison page for the side-by-side.